Prostate Cancer

Current status of immunological approaches for the treatment of prostate cancer - Abstract

Published on Friday, 30 March 2012 09:24

PURPOSE OF REVIEW:The recent Food and Drug Administration approval of sipuleucel-T for metastatic castration-resistant prostate cancer and of the anticytotoxic T-lymphocyte antigen 4 antibody (Ipilimumab) for metastatic melanoma has led to a renewed interest in immunotherapy for prostate and other cancers.

Tracking target position variability using intraprostatic fiducial markers and electronic portal imaging in prostate cancer radiotherapy - Abstract

Published on Friday, 30 March 2012 09:17

PURPOSE:Modern radiotherapy has achieved substantial improvement in tumour control and toxicity rates by escalating the total dose to the target volume while sparing surrounding normal tissues.

Predictive models for biochemical recurrence of prostate cancer after local treatment. Nomograms - Abstract

Published on Friday, 30 March 2012 09:09

In this narrative review we present the concept of nomogram in the context of predictive models in prostate cancer.

Biochemical recurrence in patients with prostate cancer after radical treatment. Comparative study of prostatectomy vs. radiotherapy - Abstract

Published on Friday, 30 March 2012 09:03

OBJECTIVES:To compare the biochemical relapse-free survival between radical prostatectomy and radiotherapy in patients with localized prostate cancer of low and intermediate recurrence risk.

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer - Abstract

Published on Friday, 30 March 2012 08:57

PURPOSE OF REVIEW:The review examines recent advances in second-line hormonal therapy for the treatment of castrate-resistant prostate cancer (CRPC).

The concept of erectile function preservation (penile rehabilitation) in the patient after brachytherapy for prostate cancer - Abstract

Published on Friday, 30 March 2012 00:16

PURPOSE:Radiation therapy (RT) for prostate cancer is commonly associated with erectile dysfunction (ED), although high-quality data on incidence of ED after brachytherapy (BT) are limited.

Evolution of treatment options for patients with CRPC and bone metastases: Bone-targeted agents that go beyond palliation of symptoms to improve overall survival - Abstract

Published on Friday, 30 March 2012 00:05

Metastasis to bone represents an all-too-frequent complication of advanced-stage prostate cancer (PCa): 50% to 70% of these patients will ultimately develop this devastating complication.

Trends in pathologic outcomes after introduction of active surveillance in the UK: Implication for focal therapy - Abstract

Published on Thursday, 29 March 2012 23:57

BACKGROUND:We aimed to evaluate the trends in pathologic outcomes of clinically localized prostate cancer treated with radical prostatectomy prior to and after national guidelines placing active surveillance as the primary management in men with low-risk prostate cancer.